Compare RENT & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RENT | SLGL |
|---|---|---|
| Founded | 2009 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.3M | 247.1M |
| IPO Year | 2021 | 2016 |
| Metric | RENT | SLGL |
|---|---|---|
| Price | $4.70 | $68.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 51.7K | 10.5K |
| Earning Date | 04-14-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.11 | N/A |
| EPS | ★ 5.10 | N/A |
| Revenue | ★ $306,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.72 | $223.84 |
| P/E Ratio | $0.88 | ★ N/A |
| Revenue Growth | ★ 2.68 | N/A |
| 52 Week Low | $3.69 | $0.40 |
| 52 Week High | $10.13 | $97.97 |
| Indicator | RENT | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 38.91 | 41.76 |
| Support Level | $4.74 | $32.56 |
| Resistance Level | $4.92 | $71.43 |
| Average True Range (ATR) | 0.33 | 11.12 |
| MACD | 0.04 | -2.76 |
| Stochastic Oscillator | 31.38 | 17.76 |
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe to, or buy designer apparel and accessories. The company gives customers access to its unlimited closet through its subscription offering (Subscription) or the ability to rent a-la-carte through its reserve offering (Reserve). The company also gives its subscribers and customers the ability to buy its products through its Resale offering. The Closet in the Cloud offers a wide assortment of items for every occasion, from evening wear and accessories to ready-to-wear, workwear, denim, casual, maternity, outerwear, blouses, knitwear, loungewear, jewelry, handbags, activewear, and ski wear.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.